ENA SCREEN, SERUM

ENA Screen, Serum

What it is

The ENA (Extractable Nuclear Antigen) Screen, Serum test detects antibodies against a group of nuclear proteins that are commonly associated with autoimmune diseases. These autoantibodies target specific antigens within the cell nucleus, and their presence helps in diagnosing connective tissue and systemic autoimmune disorders such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, systemic sclerosis, and mixed connective tissue disease (MCTD).

Uses

This test is used to evaluate patients with suspected autoimmune disorders when symptoms and ANA (antinuclear antibody) tests are positive or inconclusive. The ENA screen is typically performed as a panel, including antibodies against Sm, RNP, SSA (Ro), SSB (La), Scl-70, Jo-1, and others, depending on the laboratory. It helps guide diagnosis, monitor disease progression, and tailor treatment strategies.

Symptoms That May Lead to the Test

Doctors may recommend this test if you present with symptoms suggestive of autoimmune disease, including joint pain or swelling, unexplained rashes, dry eyes or dry mouth, muscle weakness, Raynaud’s phenomenon (discoloration of fingers in response to cold), unexplained fever, or chronic fatigue. It is often ordered following a positive ANA test.

Abnormal Results

Positive ENA Screen: Indicates the presence of one or more specific autoantibodies associated with autoimmune disease. Additional confirmatory testing may be performed to identify the exact antibody profile (e.g., anti-Sm, anti-SSA, anti-Scl-70).

Negative ENA Screen: Suggests absence of the tested autoantibodies, though autoimmune disease cannot be completely excluded. Clinical correlation with ANA and other markers is essential.

Risks

The test requires a standard blood draw. Risks are minimal and limited to mild discomfort, bruising, or dizziness at the puncture site. These are temporary and uncommon.